Specialized Manufacturing VIVEbiotech's focus on GMP-grade lentiviral vectors and their status as a GMP Contract Development and Manufacturing Organization positions them as a strategic partner for biopharmaceutical companies seeking high-quality vector production for gene therapies and advanced treatments.

Innovation Development The company’s development of the LENTISOMA non-integrative episomal lentiviral technology offers a unique product offering that could attract clients interested in safer, more efficient gene delivery solutions, opening opportunities for joint development projects.

Industry Recognition Receiving the CDMO of the Year Award and being recognized as an Excellence Centre by the European Union enhances VIVEbiotech’s credibility, making it an attractive partner for organizations looking for proven excellence and reliable collaboration in gene therapy manufacturing.

Strategic Partnerships Recent collaborations, such as the partnership with Sutargi focused on social inclusion, demonstrate VIVEbiotech’s commitment to social responsibility and community engagement, which can be leveraged to appeal to clients prioritizing corporate responsibility and ethical standards.

Market Positioning With a revenue range of $1 million to $10 million and experience working with clients across Europe and the US, VIVEbiotech presents a flexible and scalable option for biotech firms seeking to outsource development and manufacturing processes in the expanding gene therapy sector.